Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Breast 2Sarcoma 1Head & Neck 1Dermatologic 1

Conditions

Breast Neoplasms 5Ovarian Neoplasms 3Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Healthy Participants 2Endometrial Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumour 1Neoplasm Metastasis 1Moderate Hepatic Impairment 1Melanoma 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) 1Fallopian Tube Neoplasms 1Chondrosarcoma 1Advanced Solid Tumours 1Advanced Solid Malignancy, 1Advanced Solid Malignancy 1Advanced Cancer 1

Interventions

Paclitaxel 68Carboplatin 64pembrolizumab 32Cyclophosphamide 32Bevacizumab 27liposomal doxorubicin 24Cisplatin 24Topotecan 21Gemcitabine 21olaparib 18fludarabine 17Taxes 16Docetaxel 15Nivolumab 14Doxorubicin 14niraparib 13veliparib 12Albumin-Bound Paclitaxel 11aldesleukin 9Filgrastim 9fludarabine phosphate 8durvalumab 8Oxaliplatin 8Fluorouracil 8Drug Therapy 8sargramostim 7Peripheral Blood Stem Cell Transplantation 7Magnetic Resonance Spectroscopy 7Leucovorin 7talazoparib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Ovarian Neoplasms × capivasertib × Clear all
NCT05039801 2026-06-01

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Recruiting
54 enrolled
DermatologicGynecologicHead & NeckSarcoma

Squamous Cell Carcinoma of Head and Neck, Chondrosarcoma, Melanoma, Ovarian Neoplasms, Endometrial Neoplasms

NCT02208375 2025-12-31

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
159 enrolled
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT01226316 2025-06-29

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

AstraZeneca

Phase 1 Completed
285 enrolled
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡